Idelvion

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
18-09-2023
Tabia za bidhaa Tabia za bidhaa (SPC)
18-09-2023

Viambatanisho vya kazi:

albutrepenonacog alfa

Inapatikana kutoka:

CSL Behring GmbH

ATC kanuni:

B02BD04

INN (Jina la Kimataifa):

albutrepenonacog alfa

Kundi la matibabu:

Antihemorrhagics

Eneo la matibabu:

Hemophilia B

Matibabu dalili:

Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Bidhaa muhtasari:

Revision: 12

Idhini hali ya:

Authorised

Idhini ya tarehe:

2016-05-11

Taarifa za kipeperushi

                                42
B. PACKAGE LEAFLET
43
PACKAGE LEAFLET: INFORMATION FOR THE USER
IDELVION 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
IDELVION 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
IDELVION 1000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
IDELVION 2000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
IDELVION 3500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
albutrepenonacog alfa (recombinant coagulation factor IX)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have further questions, ask your doctor, pharmacist or nurse.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.

If you get any side effects talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What IDELVION is and what it is used for
2.
What you need to know before you use IDELVION
3.
How to use IDELVION
4.
Possible side effects
5.
How to store IDELVION
6.
Contents of the pack and other information
1.
WHAT IDELVION IS AND WHAT IT IS USED FOR
WHAT IS IDELVION?
IDELVION is a haemophilia medicine that replaces a natural blood
clotting (coagulation) factor IX.
The active substance in IDELVION is albutrepenonacog alfa (recombinant
fusion protein linking
coagulation factor IX with albumin (rIX-FP)).
Factor IX is involved in blood clotting. Patients with haemophilia B
have a lack of this factor which
means that their blood does not clot as quickly as it should so there
is an increased tendency to bleed.
IDELVION works by replacing factor IX in haemophilia B patients to
enable their blood to clot.
WHAT IS IDELVION USED FOR?
IDELVION is used to prevent or to halt bleeding caused by the lack of
factor IX in patients of all age
groups with haemophilia B (also called congenital factor IX deficiency
or Christ
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
IDELVION 250 IU powder and solvent for solution for injection
IDELVION 500 IU powder and solvent for solution for injection
IDELVION 1000 IU powder and solvent for solution for injection
IDELVION 2000 IU powder and solvent for solution for injection
IDELVION 3500 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
IDELVION 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with
2.5 ml water for injections the
solution contains 100 IU/ml of albutrepenonacog alfa.
IDELVION 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with
2.5 ml water for injections the
solution contains 200 IU/ml of albutrepenonacog alfa.
IDELVION 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with
2.5 ml water for injections the
solution contains 400 IU/ml of albutrepenonacog alfa.
IDELVION 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with 5
ml water for injections the
solution contains 400 IU/ml of albutrepenonacog alfa.
IDELVION 3500 IU powder and solvent for solution for injection
Each vial contains nominally 3500 IU of recombinant fusion protein
linking coagulation factor IX with
albumin (rIX-FP), (albutrepenonacog alfa). After reconstitution with 5
ml water for injections the
solution contains 700 IU/ml of albutrepenonacog alfa.
The potency (IU) is
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kibulgaria 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kihispania 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kicheki 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kidenmaki 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kijerumani 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kiestonia 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kigiriki 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kifaransa 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kiitaliano 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kilatvia 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kilithuania 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kihungari 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kimalta 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kiholanzi 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kipolandi 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kireno 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kiromania 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kislovakia 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kislovenia 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kifinlandi 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kiswidi 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 27-05-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kinorwe 18-09-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 18-09-2023
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 18-09-2023
Tabia za bidhaa Tabia za bidhaa Kroeshia 18-09-2023
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 27-05-2016

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati